Summary An ambulatory treatment regimen for multi bacillary leprosy, of 34 weeks duration composed of 8 weeks daily supervised rifampicin, ethionamide (ETH), dapsone (DDS) and clofazimine (CLO) fo llowed by 26 weeks of unsupervised ETH, DDS and CLO, introduced in 1983 has been evaluated; 268 patients were fo llowed for a mean of 4·4 years and a total of 118 8 patient years. The relapse rate was O· 33 per 100 patient years of fo llow up. The reduction of the duration of the combined administration of RMP + ETH reduced the hepatotoxi city to 1-4%. It is possible that both phases of the regimen studied could still be reduced, however in the near fu ture ETH will be replaced by alternative bactericidal drugs, avoiding the hepatotoxicity.
Previous work from our laboratoryl-4 has shown that short course treatment, ofless than 1 year's duration, is possible in multi bacillary leprosy (MB) provided combined therapy with bactericidal drugs in sufficient dosage is administered. 4 Until the end of the 1980s only 2 bactericidal drugs were available: rifampicin (RMP) and the thioamides, either ethionamide (ETH) or prothionamide, but unfortunately their combined administration is hepatotoxic,5,6 even when the duration of their combined administration was reduced to 3 months. 4 Furthermore for the supervised daily administration of drugs in our previous studies,l-4 patients had to be hospitalized or to reside in the proximity of the treatment centre. This was not always possible in Burundi.
We therefore decided to study the efficacy and tolerance of an entirely ambulatory regimen consisting of two successive phases: a first period of8 weeks ofa daily supervised 4-drug regimen including RMP, ETH, DDS and CLO fo llowed by a 6-month unsupervised triple drug regimen without RMP.
In the peripheral, rural health centre (HC), patients suspected of having leprosy were referred to the leprosy service personnel during their monthly visits, for clinical, neurological and bacteriological examinations and a skin biopsy to be fixed in 10% formalin. Slit-skin smears were taken-one from an earlobe and two from skin lesions. The biopsies together with a copy of the clinical file was sent to Antwerp, as was a copy of the treatment file when completed.
Patients were either newly diagnosed (new cases) or known cases who had been treated in the past with dapsone (DDS) monotherapy irregularly or had relapsed after DDS monotherapy had been stopped (old cases).
Patients able to visit the HC daily during the 8 weeks were included in the study and the necessary medication, in containers for daily delivery, was handed over to the responsible person in the He. Thereafter, during the second phase of treatment, medication sufficient for 4 weeks was delivered to the He. All administrations of drugs were noted on an appropriate fo rm. The treatment regimen was as follows:
8 weeks: RMP 600 mg, ETH 500 mg, DDS 100 mg, CLO 50 mg daily, 6 days a week, supervised in the HC, fo llowed by 26 weeks: ETH 500 mg, DDS 100 mg and CLO 50 mg daily 7 days a week, unsupervised, the drugs being collected from the HC once every 4 weeks.
In the present analysis only patients with a BI of 2 or more at any site, at the start of the study, are included. Treatment was considered complete if the first phase was completed within 9 weeks and the second within 30 weeks.
In the absence of any intercurrent complication fo llow-up examinations identical to those at intake were done yearly.
When relapse was suspected, clinical, bacteriological and histological examinations were repeated and if relapse was confirmed and also if fe asible, a fresh skin biopsy, on ice, was sent to the laboratory in Antwerp for mouse fo otpad inoculation and drug sensitivity testing. For the latter RMP 10 mg/k was administered to mice once a week during 10 weeks by gastric gavage, DDS was mixed in the fo od at 10-2, 10-3, 10-4%, ETH at 10-2 % and CLO at 3 . 10-3.
Results
A total of 305 patients with a BI at the start of 2 or more at any site were taken into the trial: 146 new cases and 159 old cases. Six patients died before the end of the first year from causes unrelated to leprosy. Seventeen patients (6,2%) were lost during the first phase of treatment-I because he left the country and 16 for unknown reasons. Fourteen patients (4'5%) had to be excluded from the analysis because they failed to collect their last 1 or 2 monthly doses of drugs. Thus 268 patients were evaluated, 125 new cases and 143 old cases. They were fo llowed for a mean of 4·4 years, and represent 1188 patient years of follow-up (Table 1 ). The mean BI at the start was 3·18 and declined with a mean of O' 53 per year. Clinical evolution in all patients was very satisfactory. Four cases of hepatitis (1 -4%) were diagnosed clinically at 7, 55, 68 and 208 days of treatment, with a mean of 84 days and a median of 61 days. None of them was fa tal.
Four relapses, 3 in BL patients and I in a LL patient, have been diagnosed at respectively 31, 41, 43 and 52 months after the end of treatment, with a mean and median of 42 months. One relapse was detected in a yearly fo llow-up biopsy, the other 3 cases were detected clinically.
Bacilli from 3 relapses were inoculated into mice, all were sensitive to the drugs administered to the patients.
Six cases oflate reversal reactions were diagnosed at respectively 29, 30, 40, 41, 56 and 57 months after the end of treatment with a mean of 42 months and a median of 40·5 months. Five had been classified as BL and one as LL.
Discussion
The present study shows that MB leprosy can be cured by an ambulatory treatment of 8 months duration, composed of a daily supervised administration of 4 drugs, 2 of which, RMP and ETH are bactericidal, fo llowed by 6 months of unsupervised administration of 3 drugs, one of which, ETH, is bactericidal.
The 48 doses of RMP administered during the first 8 weeks of treatment are supposed to kill all RMP sensitive organisms, while the 230 doses of ETH, DDS and CLO administered during the next 8 months should kill the remaining RMP-resistant organisms.5 The relapse rate of O·3% of the present 8+26 weeks (w) regimen, compares fa vourably with the previously studied 13w regimen for which the relapse rate was 0·28%. It must be noted however that the follow-up for the 8 + 26w regimen of 4-4 years or 53 months is longer than for the 13w regimen for which it was 3· 5 years or 42 months. Compared with the l3w regimen,4 the 8+26w regimen implies the administration of greater quantities of drugs during a longer time period: There is no evidence that the 14 patients who fa iled to collect their final one or two drug supplies did so because of hepatitis: they were also fo llowed for 4-5 years and none of them developed a relapse. This supports the hypothesis and it may be possible to reduce the duration of the second phase in the present regimen, but the number of patients is too small to allow significant conclusions to be drawn.
As expected after treatment with a combined drug regimen, the strains isolated from the relapsing patients were sensitive to the drugs the patients had taken. This shows that in a small proportion of MB patients, some drug sensitive My cobacterium leprae escape the action of the drugs and give rise to relapses, it is possible that a combination of more than 2 bactericidal drugs may solve this problem.
Once more the late reversal reactions, appearing in the present study after a mean of 42 months post-therapy should be differentiated from relapses on the basis of careful bacteriological and histopathological assessment.
In conclusion a treatment regimen of MB leprosy of 34 weeks duration, involving 8 weeks of daily supervised RMP, ETH, DDS and CLO fo llowed by 26 weeks of unsupervised ETH, DDS and CLO gave most satisfactory results in terms of relapse rate while at the same time hepatotoxicity was reduced considerably.
